CytoDyn Inc. (OTCMKTS:CYDY) Sees Significant Growth in Short Interest

CytoDyn Inc. (OTCMKTS:CYDY) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totalling 12,982,100 shares, an increase of 20.1% from the August 31st total of 10,806,600 shares. Based on an average daily volume of 4,913,500 shares, the days-to-cover ratio is presently 2.6 days.

CytoDyn Stock Performance

OTCMKTS:CYDY remained flat at $0.16 during trading hours on Monday. 1,690,023 shares of the company’s stock traded hands, compared to its average volume of 2,515,076. The firm has a 50-day moving average of $0.14 and a 200 day moving average of $0.15. CytoDyn has a twelve month low of $0.11 and a twelve month high of $0.42. The stock has a market capitalization of $167.44 million, a P/E ratio of -3.17 and a beta of 0.12.

CytoDyn (OTCMKTS:CYDY) last issued its quarterly earnings results on Thursday, August 15th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.